From the results of the serum tumor marker levels, the level of NSE, CEA, associated antigen of SCC, and CA19-9 of patients in the experiment group was 18.43 ± 1.05 ng/mL, 14.03 ± 1.12 ng/mL, 0.95 ± 0.33 ng/mL, and 64.72 ± 8.45 U/mL, respectively, which was significantly lower than those in the control group (P < 0.05). The gene discussed is ENO2; the disease is neoplasm.